Molina Healthcare (NYSE:MOH) has gained numerous interest from investors due to its notable returns of 75% over the past five years. It has been garnering attention for its significant growth, especially after Cantor Fitzgerald issued a 'Buy' rating. Despite an $880 billion cut to Medicaid, the company shows growth potential and has caught the eye of the Russell 1000 index, too. Morgan Stanley has given the health provider a positive outlook. Recently, Molina saw a big boost in its stock when premium revenue surged.
Athough their Q4 sales were better than expected, the stock did drop. In their Q1 2025 results, they beat revenue estimates and in 2024, MOH reported a YoY increase in revenue reaching US$40,650 million. MOH showed strength in its Medicaid earnings and was highlighted for having huge upside potential. Furthermore, they were added to the portfolio of notable investors such as Oakmark Equity, Income Fund, and Michael Burry.
Attracting analysts' attention for its value and performance, Molina Healthcare nevertheless faced slight underperformance compared to the S&P 500. Operational and political challenges do exist, but the consensus among analysts leans on the bullish side. The company is set to reveal its Q2 2025 results in an upcoming earnings call.
Molina Healthcare MOH News Analytics from Sun, 20 Oct 2024 07:00:00 GMT to Sat, 21 Jun 2025 19:02:35 GMT - Rating 7 - Innovation 6 - Rumor -1
